Trioxacarcin B  (Synonyms: TXN-B)

Trioxacarcin B (TXN-B) is a potent cytotoxic agent and DNA-targeted inhibitor. Trioxacarcin B disrupts DNA function and induces apoptosis in cancer cells. Trioxacarcin B not only effectively inhibits the growth of various Gram-positive and Gram-negative bacteria as well as Plasmodium falciparum, but also blocks the colony formation of cancer stem cells, significantly reduces tumor volume and prolongs survival in preclinical in vivo models. The activity of Trioxacarcin B is highly dependent on its intact spiro-epoxide structure; it loses efficacy once this moiety undergoes hydrolysis, and Trioxacarcin B shows no activity against fungi, microalgae and small RNA viruses. Trioxacarcin B can be used for research on bacterial infections, malaria, and various cancers including colon cancer and melanoma^[1][2][3].

Trioxacarcin B (30~40 μg; 9 mm culture dish) exhibits in vitro antimicrobial activity against Bacillus subtilis, Escherichia coli, Staphylococcus aureus, and Streptomyces viridochromogenes Tu 57; the diameters of the inhibition zones are 38 mm, 32 mm, 22 mm, and 27 mm, respectively^[2].
Trioxacarcin B exhibits in vitro inhibitory activity against Plasmodium falciparum strains K1 and NF54, with mean IC₅₀ values of 102 ng/mL and 82 ng/mL, respectively, following 24 h of treatment^[2].
Trioxacarcin B exhibits in vitro antitumor activity against a panel of permanent human tumor cell lines, with a mean IC₅₀ of 1.107 μg/mL and a mean IC₇₀ of 2.161 μg/mL, and its activity varies across different cell lines^[2].
Trioxacarcin B inhibits the colony formation of tumor stem cells derived from LXFL 529 large cell lung cancer xenografts in vitro, with an IC₅₀ of 6.0 ng/mL, an IC₇₀ of 25.0 ng/mL, and an IC₉₀ of 157.0 ng/mL^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

894.87

C₄₂H₅₄O₂₁

81534-36-3

CC1=C(C(O2)=C3C(C(OC)=C4C(C([C@H](C[C@@H]4O[C@H]5C[C@@](O)([C@@H]([C@@H](O5)C)OC(C)=O)C)O)=O)=C3O)=C1)[C@@](O[C@]([C@]6(O)CO)(O7)C(OC)OC)([H])[C@@]7([H])[C@@]26O[C@H]8C[C@H]([C@](O)([C@@H](O8)C)C(C)=O)O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gruchot W. Trioxacarcin-based Antibody-Drug Conjugates: Optimization of payload structure and a triazene linker system design[D]. Harvard University, 2026.

  [2]. Maskey RP, et al. Anti-cancer and antibacterial trioxacarcins with high anti-malaria activity from a marine Streptomycete and their absolute stereochemistry. J Antibiot (Tokyo). 2004;57(12):771-779.  [Content Brief]